Skip to main content
SpringerLink
Log in

Epidemiology Incidence and Risk Factors for Invasive Candidiasis in High-Risk Patients

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Candida spp. are an increasing cause of bloodstream infections, and are associated with high morbidity and mortality in both neutropenic and non-neutropenic critically ill patients. Risk factors associated with candidaemia are diverse and include exposure to broad spectrum antimicrobial agents, mucosal colonization by Candida spp., indwelling vascular catheters, prior surgery and cancer chemotherapy. During the last 20 years, there has been an increasing incidence worldwide in invasive candidiasis, but differences in geographical epidemiology are emerging, in particular regarding a shift towards non -albicans species. This shift has been correlated with routine fluconazole prophylaxis adopted in some patients, and the intrinsic/acquired azole resistance of Candida spp., which represents a very real problem, in terms of both selecting the appropriate empirical therapeutic approach and making prophylactic choices.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Blumberg HM, Jarvis WR, Soucie JM, et al., and the NEMIS Study Group. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001; 33: 177–86

    Article  PubMed  CAS  Google Scholar 

  2. Almirante B, Rodriguez D, Park BJ, et al., and the Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829–35

    Article  PubMed  Google Scholar 

  3. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685–702

    Article  PubMed  Google Scholar 

  4. Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41: 1455–60

    Article  PubMed  Google Scholar 

  5. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–7

    Article  PubMed  CAS  Google Scholar 

  6. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521–6

    Article  PubMed  Google Scholar 

  7. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551–7

    Article  PubMed  CAS  Google Scholar 

  8. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419–31

    Article  PubMed  CAS  Google Scholar 

  9. Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in San Francisco Bay Area, 1992–1993: results of a population-based laboratory active surveillance. Clin Infect Dis 1998; 27: 1138–47

    Article  PubMed  CAS  Google Scholar 

  10. Segal BH, Kwon-Chung J, Walsh TJ, et al. Immunotherapy for fungal infections. Clin Infect Dis 2006; 42: 507–15

    Article  PubMed  CAS  Google Scholar 

  11. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26–34

    Article  PubMed  Google Scholar 

  12. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546–54

    Article  PubMed  Google Scholar 

  13. Chen YC, Chang SC, Luh KT, et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003; 52: 71–7

    Article  PubMed  CAS  Google Scholar 

  14. Malani A, Hmoud J, Chiu L, et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect. Dis 2005; 41: 975–81

    Article  PubMed  Google Scholar 

  15. Malani PN, Bradley SF, Little RS, et al. Trends in species causing fungemia in a tertiary care medical centre over 12 years. Mycoses 2001; 44: 446–9

    Article  PubMed  CAS  Google Scholar 

  16. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634–43

    Article  PubMed  Google Scholar 

  17. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46: 1723–7

    Article  PubMed  CAS  Google Scholar 

  18. Pfaller MA, Diekema DJ, Rinaldi MG, et al., and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848–59

    Article  PubMed  CAS  Google Scholar 

  19. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro suceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006; 44: 760–3

    CAS  Google Scholar 

  20. Puzniak L, Teutsch S, Powderly W, et al. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 2004; 25: 628–33

    Article  PubMed  Google Scholar 

  21. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and number of isolates with reduced azole susceptibility. J Clin Microbiol 2005; 43: 4434–40

    Article  PubMed  CAS  Google Scholar 

  22. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nation-wide study in Iceland. J Clin Microbiol 2002; 40: 3489–92

    Article  PubMed  Google Scholar 

  23. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J Clin Microbiol 2002; 40: 1298–302

    Article  PubMed  CAS  Google Scholar 

  24. Hajjeh RA, Sofair AN, Harrison IH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519–27

    Article  PubMed  Google Scholar 

  25. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164–70

    Article  PubMed  CAS  Google Scholar 

  26. Sandven P, Bevanager L, Digranes A, et al., and the Norwegian Yeast Study Group. Candidemia in Norway, 1991 to 2003: results from a nationwide study. J Clin Microbiol 2006; 44: 1977–81

    Article  PubMed  Google Scholar 

  27. Jarvis WR. Epidemiology of nosocomial fungal infection, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526–30

    Article  PubMed  CAS  Google Scholar 

  28. Voss A. Therapeutic approach to the patient with candidemia. Clin Microbiol Infect 1999; 5 Suppl. 2: S54–S7

    Google Scholar 

  29. Ostrosky-Zeichner L, Rex JH, Bennett J, et al. Deeply invasive candidiasis. Infect Dis Clin North Am 2002; 16: 821–35

    Article  PubMed  Google Scholar 

  30. Hull CM, Raisner RM, Johnson ADS. Evidence for mating of the asexual yeast Candida albicans in a mammalian host. Science 2000; 289: 307–10

    Article  PubMed  CAS  Google Scholar 

  31. Edwards Jr JE. Invasive candida infections-evolution of a fungal pathogen. N Engl J Med 1991; 324: 1060–2

    Article  PubMed  Google Scholar 

  32. Miller MG, Johnson AD. White-opaque switching in Candida albicans is controlled by mating-type locus homeodomain proteins and allows efficient mating. Cell 2002; 110: 293–302

    Article  PubMed  CAS  Google Scholar 

  33. Safdar A, Pertin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11–6

    Article  PubMed  Google Scholar 

  34. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662–78

    Article  PubMed  CAS  Google Scholar 

  35. Blot S, Dimopoulos G, Rello J, et al. Is Candida really a threat in the ICU? Curr Opin Crit Care 2008; 14: 600–4

    Article  PubMed  Google Scholar 

  36. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133–63

    Article  PubMed  CAS  Google Scholar 

  37. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007; 50: 302–10

    Article  PubMed  Google Scholar 

  38. Rello J, Esandi ME, Diaz E, et al. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998; 114: 146–9

    Article  PubMed  CAS  Google Scholar 

  39. Azoulay E, Cohen Y, Zahar JR, et al. Practices in non-neutropenic ICU patients with Candida-positive airway specimens. Intensive Care Med 2004; 30: 1384–9

    PubMed  Google Scholar 

  40. Alexander BD, Pfaller AM. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43 Suppl. 1: S15–27

    Article  CAS  Google Scholar 

  41. Morrell M, Fraser VJ, Kollef MJ. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob Agents Chemother 2005; 49: 3640–5

    Article  PubMed  CAS  Google Scholar 

  42. Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000; 15: 83–90

    Article  CAS  Google Scholar 

  43. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857–63

    Article  PubMed  Google Scholar 

  44. Vardakas KZ, Samonis G, Michalopoulos A, et al. Anti-fungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006; 34: 1216–24

    Article  PubMed  CAS  Google Scholar 

  45. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533–7

    Article  PubMed  Google Scholar 

  46. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microb Infect Dis 2004; 23: 739–44

    Article  CAS  Google Scholar 

  47. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43: 235–43

    Article  PubMed  Google Scholar 

  48. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443–9

    Article  PubMed  Google Scholar 

  49. Rex JH. Antifungal prophylaxis in the intensive care unit: who should get it? Crit Care Med 2006; 34: 1286–7

    Article  PubMed  Google Scholar 

  50. Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy. Clin Infect Dis 2001; 33: 187–90

    Article  PubMed  CAS  Google Scholar 

  51. Wisplinghoff H, Bischoff T, Tallent H, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309–17

    Article  PubMed  Google Scholar 

  52. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. 2005; 41 Suppl. 6: S389–93

    Google Scholar 

  53. Trick WE, Fridkin SK, Edwards JR, et al., and the National Nosocomial Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 2002; 35: 622–30

    Article  Google Scholar 

  54. Poikonen E, Lyytikanien O, Anttila VJ, et al. Candidemia in Finland, 1995–1999. Emerg Infect Dis 2003; 9: 985–90

    Article  PubMed  Google Scholar 

  55. Tortorano AM, Kibbler C, Peman J, et al. Candidemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359–66

    Article  PubMed  CAS  Google Scholar 

  56. Richet H, Andremont A, Roux P, et al. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002; 8: 405–12

    Article  PubMed  CAS  Google Scholar 

  57. Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia in non-neutropenic patients in an Italian tertiary care center. Eur J Clin Microbiol Infect Dis 2000; 19: 602–7

    Article  PubMed  CAS  Google Scholar 

  58. Garbino J, Kolarova L, Rohner P, et al. Secular trends in of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 2002; 81: 425–33

    Article  PubMed  Google Scholar 

  59. Leleu G, Aegerter P, Guidet B, for College des Utilisateurs de Base de Donnees en reanimation. Systemic candidiasis in intensive care units: a multicenter matched-cohort study. J Critical Care 2002; 17: 168–75

    Article  Google Scholar 

  60. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917–21

    Article  PubMed  CAS  Google Scholar 

  61. Sobel JD. Changing epidemiology of invasive candidiasis in intensive care units — Much ado about nothing? Crit Care Med 2008; 36: 2188–9

    Article  PubMed  Google Scholar 

  62. Debusk CH, Daoud R, Thirumoorthi MC, et al. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand J Infect Dis 1994; 26: 697–703

    Article  PubMed  CAS  Google Scholar 

  63. Sandven P, Bevanger L, Digranes A, et al. Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol 1998; 36: 3455–9

    PubMed  CAS  Google Scholar 

  64. Doczi I, Dosab E, Hajdu E, et al. Aetiology and antifungal susceptibility of yeasts bloodstream infections in a Hungarian university hospital between 1996 and 2000. J Med Microbiol 2002; 51: 677–81

    PubMed  Google Scholar 

  65. Kremery VJ, Kovacicova G. Longitudinal 10-year prospective survey of fungaemia in Slovak republic: trends in etiology in 310 episodes. Diagn Microbiol Infect Dis 2000; 36: 7–11

    Article  Google Scholar 

  66. Mathews MS, Samuel PR, Suresh M. Emergence of Candida tropicalis as the major cause of fungaemia in India. Mycoses 2001; 44: 278–80

    Article  PubMed  CAS  Google Scholar 

  67. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414–21

    Article  PubMed  CAS  Google Scholar 

  68. Girmenia C, Martino P. Fluconazole and the changing epidemiology of candidemia. Clin Infect Dis 1998; 27: 232–4

    Article  PubMed  CAS  Google Scholar 

  69. Abi-Said D, Anaisse E, Uzun O, et al. The epidemiology of hematogenous candidiasis by different Candida species. Clin Infect Dis 1997; 24: 1122–8

    Article  PubMed  CAS  Google Scholar 

  70. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1995; 39: 40–4

    Article  Google Scholar 

  71. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246–54

    Article  Google Scholar 

  72. Marchetti O, Bille J, Fluckinger U, et al. Epidemiology of candidmia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 2004; 38: 311–20

    Article  PubMed  Google Scholar 

  73. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555–60

    Article  PubMed  CAS  Google Scholar 

  74. Levin AS, Costa SF, Mussi NS, et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998; 30: 243–9

    Article  PubMed  CAS  Google Scholar 

  75. Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21

    Article  PubMed  Google Scholar 

  76. Marr KA, Seidel K, White TC, et al. Candidemia in allogenic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–16

    Article  PubMed  CAS  Google Scholar 

  77. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, M27-A2. 2nd ed. Wayne (PA): National Committee for Clinical Laboratory Standards, 2002

    Google Scholar 

  78. National Committee for Clinical Laboratory Standards. Methods for antifungal disk diffusion susceptibility testing of yeasts: approved guideline, M44-A. Wayne (PA): National Committee for Clinical Laboratory Standards, 2004

    Google Scholar 

  79. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999; 43: 1289–90

    PubMed  CAS  Google Scholar 

  80. Krogh-Madsen M, Arendrup MC, Heslet L, et al. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938–44

    Article  PubMed  CAS  Google Scholar 

  81. Viudes A, Peman J, Canton E, et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002; 21: 767–4

    Article  PubMed  CAS  Google Scholar 

  82. Alonso-Valle H, Acha O, Garcia-Palomo JD, et al. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254–7

    PubMed  CAS  Google Scholar 

  83. Bregenzer T, Evison-Eckstein AC, Frei R, et al. Clinical aspects and prognosis of candidemia, a 6-year retrospective study. Schweiz Med Wochenschr 1996; 126: 1829–33

    PubMed  CAS  Google Scholar 

  84. Blot SI, Vandewoude KH, Hoste EA, et al. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480–5

    Article  PubMed  Google Scholar 

  85. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23–30

    Article  PubMed  CAS  Google Scholar 

  86. Voss A, le Noble JL, Verduyn LF, et al. Candidemia in intensive care unit patients: risk factors for mortality. Infection 1997; 25: 8–11

    Article  PubMed  CAS  Google Scholar 

  87. Garrouste-Orgeas M, Timsit JF, Tafflet M, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006; 42: 1118–26

    Article  PubMed  Google Scholar 

  88. Diekema DJ, Pfaller MA. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004; 25: 624–6

    Article  PubMed  Google Scholar 

  89. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273–84

    Article  PubMed  CAS  Google Scholar 

  90. Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 334: 1437–40

    Article  Google Scholar 

  91. Samonis G, Gikas A, Anaisse EJ, et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastro-intestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37: 51–3

    Article  PubMed  CAS  Google Scholar 

  92. Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia 1985; 23: 265–73

    Article  PubMed  CAS  Google Scholar 

  93. Pittet D, Monod M, Filthuth I, et al. Contour-clamped homogeneous electric field gel electrophoresis as a powerful epidemiologic tool in yeast infections. Am J Med 1991; 91: 256–63S

    Article  Google Scholar 

  94. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43 Suppl. 1: S3–14

    Article  CAS  Google Scholar 

  95. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751–8

    Article  PubMed  CAS  Google Scholar 

  96. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730–7

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Marie Cheeseman of Wolters Kluwer Pharma Solutions, who provided assistance with English language editing. This assistance was funded by Pfizer. Dr Concia, Dr Azzini and Dr Conti have no conflicts of interest relevant to the contents of this review.

Author information

Authors and Affiliations

  1. Department of Pathology, Infectious Disease Unit, University of Verona, c/o Infectious Disease Unit, Policlinico “G. B. Rossi”, P.le L.A. Scuro, 37100, Verona, Italy

    Ercole Concia,  Anna Maria Azzini & Michela Conti

Authors
  1. Ercole Concia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Maria Azzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michela Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Maria Azzini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Concia, E., Azzini, A.M. & Conti, M. Epidemiology Incidence and Risk Factors for Invasive Candidiasis in High-Risk Patients. Drugs 69 (Suppl 1), 5–14 (2009). https://doi.org/10.2165/11315500-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11315500-000000000-00000

Keywords

Search

Navigation